Adding Cytokines to Monoclonal Antibody Therapy: Does the Concurrent Administration of Interleukin-12 Add to the Efficacy of Rituximab in B-cell Non-Hodgkin Lymphoma?

References

• Greenlee, R.T., Hill-Harmon, M.B., Murray, T. and Thun, M. (2001) "Cancer statistics", CA Cancer J. Clin. 2001 51(1), 15–36.
   Google Scholar
• Ansell, S.M., Stenson, M., Habermann, T.M., Jelinek, D.F. and Witzig, T.E. (2001) "The CD4 T-cell immune response to B-cell large cell non-Hodgkin's lymphoma predicts patient outcome", J. Clin. Oncol. 19, 720–726.
   PubMed Web of Science ®Google Scholar
• Kobayashi, M., Fitz, L., Ryan, M., Hewick, R.M., Clark, S.C., Chan, S., Loudon, R., Sherman, F., Perussia, B. and Trinchieri, G. (1989) "Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes", J. Exp. Med. 170, 827–845.
   PubMed Web of Science ®Google Scholar
• Stern, AS., Podlaski, F.J., Hulmes, J.D., Pan, YE., Quinn, P.M., Wolitzky, A.G., Familetti, P.C., Stremlo, D.L., Truitt, T., Chizzonite, R. and Gately, M.K. (1990) "Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells", Proc. Natl Acad. Sci. USA 87, 6808–6812.
   PubMed Web of Science ®Google Scholar
• Banks, R.E., Patel, P.S. and Selby, P.J. (1995) "Interleukin-12: a new clinical player in cytokine therapy", Br. J. Cancer 71, 655–659.
   PubMed Web of Science ®Google Scholar
• Brunda, M.J. (1997) "Interleukin-12", J. Leukoc. Biol. 55, 280–288.
   Google Scholar
• Galetti, T.P. (1993) "Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune response to tumors", Cancer Investig. 11, 500–506.
   PubMed Web of Science ®Google Scholar
• Brunda, M.J., Luistro, L., Warner, R.R., Wright, R.B., Hubbard, BR., Murphy, M., Wolf, S.F. and Gately, M.K. (1993) "Antitumor and antimetastatic activity of interleukin-12 against murine tumors", J. Exp. Med. 178, 1223–1230.
   PubMed Web of Science ®Google Scholar
• Voest, E.E., Kenyon, B.M., O'Reilly, M., Truitt, G., Amato, R.J. and Folkman, J. (1995) "Inhibition of angiogenesis in vivo by interleukin-12", J. Natl Cancer Inst. 87, 581–586.
   PubMed Web of Science ®Google Scholar
• Nastala, C.L., Edington, H.D., McKinney, T.G., Tahara, H., Nalesnik, M.A., Brunda, M.J., Gately, M.K., Wolf, S.F., Schreiber, Storkus, W.J. and Lotze, M.T. (1994) "Recombinant IL-12 administration induces tumor regression in association with 1FN gamma production", J. Immunol. 53, 1697–1706.
   PubMed Web of Science ®Google Scholar
• Brunda, M.J., Luistro, L., Hendrazak, LA., Fountoulakis, M., Garotta, G. and Gately, M.K. (1995) "Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12", J. Immunother. 17, 71.
   PubMed Web of Science ®Google Scholar
• Sieburth, D., Jabs, E.W., Warrington, J.A., Li, X., Lasota, J., LaForgia, S., Kelleher, K., Huebner, K., Wasmuth, J.J. and Wolf, S.F. (1992) "Assignment of genes encoding a unique cytokine (IL-IL-12) composed of two unrelated subunits to chromosomes 3 and 5", Genomics 14, 59–62.
   PubMed Web of Science ®Google Scholar
• Tannenbaum, CS., Wicker, N., Armstrong, D., Tubbs, R., Finke, J., Bukowski, R.M. and Hamilton, T.A. (1996) "Cytokine and chemokine expression in mice receiving systemic therapy with IL-12", J. Immunol. 156, 693.
   PubMed Web of Science ®Google Scholar
• Tannenbaum, CS., Tubbs, R., Armstrong, D., Finke, J., Bukowski, R.M. and Hamilton, T.A. (1998) "The CXC chemokines 1P-10 and Mig are necessary for IL-12 mediated regression of the mouse RENCA tumor", J. Immunol. 161, 927–932.
   PubMed Web of Science ®Google Scholar
• Yu, W.G., Ogawa, M., Mu, J., Umehara, K., Tsujimura, T., Fujiwara, H. and Hamaoka, T. (1997) "IL-12-induced tumor regression correlates with in situ activity of 1FN-y produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways", J. Leukoc. Biol. 62, 450–457.
   PubMed Web of Science ®Google Scholar
• Leonard, LP., Sherman, M.L., Fisher, G.L., Buchanan, L.J., Larsen, G., Atkins, M.B., Sosman, J.A., Dutcher, LP., Vogelzang, N.J. and Ryan, J.L. (1997) "Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma pro-duction", Blood 90, 2541–2548.
   PubMed Web of Science ®Google Scholar
• Motzer, R.J., Rakhit, A., Schwarts, L.H., Olencki, T., Malone, T.M., Sandstrom, K., Nadeau, R., Parmar, H. and Bukowski, R. (1998) "Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma", Clin. Cancer Res. 4, 1183–1191.
   PubMed Web of Science ®Google Scholar
• Atkins, M.B., Robertson, M.J., Gordon, M., Lotze, M.T., DeCoste, M., DuBois, J.S., Ritz, J., Sandler, A.B., Edington, H.D., Garzone, P.D., Mier, LW., Canning, C.M., Battiato, L., Tahara, H. and Sherman, M.L. (1997) "Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies", Clin. Cancer Res. 3, 409 —417.
   PubMed Web of Science ®Google Scholar
• Younes, A., Robertson, M.J., Flinn, I.W., Romaguera, J., Hagemeister, F.B., Cabanillas, F., Rodriguez, M.A., Dang, N. and Samaniego, F. (2002) "A phase 11 study of interleukin-12 (IL-12) in patients with relapsed non-Hodgkin lymphoma and Hodgkin disease (abstract)", American Society of Hematology 44th Annual Meeting.
   Google Scholar
• Valentine, M.A., Meier, K.E., Rossie, S., et al. (1989) "Phos-phorylation of the CD20 phosphoprotein in resting B lymphocytes", J. Biol. Chem. 264, 11282–11287.
   PubMed Web of Science ®Google Scholar
• Einfeld, D.A., Brown, J.P., Valentine, M.A., et al. (1988) "Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains", EMBO J. 7,711–717.
   PubMed Web of Science ®Google Scholar
• Reff, M.E., Canner, K., Chambers, KS., Chinn, P.C., Leonard, J.E., Raab, R., Newman, R.A., Hanna, N. and Anderson, D.R. (1994) "Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20", Blood 83, 435–445.
   PubMed Web of Science ®Google Scholar
• Anderson, K.C., Bates, M.P., Sleughenhoupt, B.L., et al. (1984) "Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation", Blood 63, 1424–1433.
   PubMed Web of Science ®Google Scholar
• Tedder, T.F., Boyd, A.W., Freedman, AS., et al. (1985) "The B cell surface molecule B1 is functionally linked with B cell activation and differentiation", J. Immunol. 135, 973–979.
   PubMed Web of Science ®Google Scholar
• Shan, D., Ledbetter, J.A. and Press, 0.W. (2000) "Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells", Cancer Immunol. Immunother 48, 673–683.
   PubMed Web of Science ®Google Scholar
• Hofmeister, J.K., Cooney, D. and Coggeshall, K.M. (2000) "Clustered CD20 induced apoptosis: Src-family kinase, the proximal regulator of tyrosine phosphorylation calcium influx and caspase 3-dependent apoptosis", Blood Cells MoL Dis. 26, 133 —143.
   PubMed Web of Science ®Google Scholar
• Golay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.M., Bernasconi, S., Tedesco, F., Rambaldi, A. and Introna, M. (2000) "Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis", Blood 95, 3900–3908.
   PubMed Web of Science ®Google Scholar
• Harjunpaa, A., Junnikkala, S. and Merl, S. (2000) "Rituximab (anti-CD20) therapy of B cell lymphomas: direct complement killing is superior to cellular effector mechanisms", Scand. J. Immunol. 51, 634–641.
   PubMed Web of Science ®Google Scholar
• Wurflein, D., Dechant, M., Stockmeyer, B., Tutt, AL., Hu, P., Repp, R., Kalden, J.R., van de Winkel, J.G., Epstein, AL., Valerius, T., Glennie, M. and Gramatzld, M. (1998) "Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells", Cancer Res. 58, 3051–3058.
   PubMed Web of Science ®Google Scholar
• Stockmeyer, B., Valerius, T., Repp, R., Heijnen, LA., Buhring, H.J., Deo, Y.M., Kalden, J.R., Gramatzki, M. and van de Winkel, J.G. (1997) "Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer", Cancer Res. 57, 696–701.
   PubMed Web of Science ®Google Scholar
• Elsasser, D., Valerius, T., Repp, R., Weiner, G.J., Deo, Y, Kalden, J.R., van de Winkel, J.G., Stevenson, G.T., Glennie, M.J. and Gramatzki, M. (1996) "HLA class 11 as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor", Blood 87, 3803–3812.
   PubMed Web of Science ®Google Scholar
• Valerius, T., Repp, R., de Wit, T., Berthold, S., Platzer, E., Kalden, J.R., Gramatzki, M. and van de Winkel, J. (1993) "Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy", Blood 82, 931–939.
   PubMed Web of Science ®Google Scholar
• Ottonello, L., Morone, P., Dapino, P. and Dallegri, F. (1996) "Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokinine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes", Blood 87, 5171–5178.
   PubMed Web of Science ®Google Scholar
• Cemerlic, D., Dadey, B., Han, T. and Vaickus, L. (1991) "Cytokine influence on killing of fresh chronic lymphocytic leukemia cells by human leukocytes", Blood 77, 2707–2715.
   PubMed Web of Science ®Google Scholar
• Coiffier, B., Haioun, C., Kenerer, N., Engem A., Tilly, H., Ma, D., Johnson, P., Lister, A., Feuring-Buske, M., Radford, LA., Capdeville, R., Diehl, V. and Reyes, F. (1998) "Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase 11 study", Blood 92, 1927–1932.
   Web of Science ®Google Scholar
• McLaughlin, P., Gillo-López, A., Link, BK., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V, Ho, A.D., Lister, J., Wey, K., Shen, D. and Dallaire, B.K. (1998) "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program", J. Clin. Oncol. 16, 2825–2833.
   PubMed Web of Science ®Google Scholar
• Davis, T.A., White, C.A., Grillo-López, A., Velasquez, W.S., Link, B., Maloney, D.G., Dillman, R.O., Williams, M.E., Mohrbacher, A., Weaver, R., Dowden, S. and Levy, R. (1999) "Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase 11 trial of rituximab", J. Clin. Oncol. 17, 1851–1857.
   PubMed Web of Science ®Google Scholar
• Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., Janakiraman, N., Foon, K.A., Liles, TM., Dallaire, BK., Wey, K., Royston, I., Davis, T. and Levy, R. (1997) 1DEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma", Blood 90(6), 2188 — 2195.
   Google Scholar
• Grillo-Lopez, A.J., White, C.A., Varns, C., Shen, D., Wei, A., McClure, A. and Dallaire, B.K. (1999) "Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma", Semin. Oncol. 26(5 Suppl. 14), 66–73.
   PubMed Web of Science ®Google Scholar
• Foran, J.M., Rohatiner, AZ., Cunningham, D., Popescu, R.A., Solal-Celigny, P., Ghielmini, M., Coiffier, B., Johnson, P.W., Gisselbrecht, C., Reyes, F., Radford, J.A., Bessel, EM., Souleau, B., Benzohra, A. and Lister, T.A. (2000) "European phase 11 study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma", J. Clin. Oncol. 18(2), 317–324.
   PubMed Web of Science ®Google Scholar
• Hainsworth, J.D., Burris, H.A., Morrissey, L.H., Litchy, S., Scullin, D.C., Bearden, J.D., Richards, P. and Greco, F.A. (2000) "Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma", Blood 95(10), 3052–3056.
   PubMed Web of Science ®Google Scholar
• Colombat, P., Salles, G., Brousse, N., Eftekhari, P., Soubeyran, P., Delwail, V, Deconinck, E., Haioun, C., Foussard, C., Sebban, C., Stamatoullas, A., Milpied, N., Boue, F., Taillan, B., Lederlin, P., Najman, A., Thieblemont, C., Montestruc, F., Mathieu-Boue, A., Benzohra, A. and Solal-Celigny, P. (2001) "Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation", Blood 97(1), 101–106.
   PubMed Web of Science ®Google Scholar
• Foran, J.M., Cunningham, D., Coiffier, B., Solal-Celigny, P., Reyes, F., Ghielmini, M., Johnson, P.W., Gisselbrecht, C., Bradburn, M., Matthews, J. and Lister, T.A. (2000) "Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response", Ann. Oncol. 11\(Suppl. 1), 117–121.
   PubMed Web of Science ®Google Scholar
• Parihar, R., Dierksheide, J., Hu, Y. and Carson, WE. (2002) "IL-12 enhance the natural killer cell cytokine response to Ab-coated tumor cells", J. Clin. Investig. 110(7), 983–992.
   Google Scholar
• Ansell, S.M., Witzig, T.E., Kurtin, P.J., Sloan, J.A., Jelinek, D.F., Howell, KG., Markovic, S.N., Habermann, TM., Klee, G.G., Atherton, P.J. and Erlichman, C. (2002) "Phase 1 study of interleukin-12 in combination with rituximab in patients with B-Cell non-Hodgkin lymphoma", Blood 99(1), 67–74.
   PubMed Web of Science ®Google Scholar
• Dierksheide, J.E., Marsh, C., Caligiuri, MA. and Carson, WE. (1999) "Fc receptor cross-linking in the presence of IL-12 is a potent stimulus to natural killer production of interferon-{gamma]: implications for her2 antibody therapy", Proc. AACR, 516.
   Google Scholar